Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
5.55
-0.19 (-3.23%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Evolus Employees
Evolus had 350 employees as of March 31, 2026. The number of employees increased by 16 or 4.79% since the number was last reported on December 31, 2025.
Employees
350
Change
16
Growth
4.79%
Revenue / Employee
$862,260
Profits / Employee
-$124,066
Market Cap
365.16M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 350 | 16 | 4.79% |
| Dec 31, 2025 | 334 | 2 | 0.60% |
| Dec 31, 2024 | 332 | 59 | 21.61% |
| Dec 31, 2023 | 273 | 58 | 26.98% |
| Dec 31, 2022 | 215 | 48 | 28.74% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tilray Brands | 2,842 |
| Canopy Growth | 1,128 |
| Emergent BioSolutions | 900 |
| Organogenesis Holdings | 854 |
| Kamada | 462 |
| Zhengye Biotechnology Holding | 269 |
| Akebia Therapeutics | 194 |
| Alpha Teknova | 158 |
EOLS News
- 10 days ago - Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 12 days ago - Evolus partners with IBSA to develop and market Profhilo in the U.S. - TheFly
- 12 days ago - Evolus Announces Partnership with IBSA to Develop and Commercialize Market-Leading Profhilo® in the United States, Expanding Its Injectable Portfolio into Skin Quality - Business Wire
- 5 weeks ago - Evolus Transcript: AGM 2026 - Transcripts
- 6 weeks ago - Evolus files $250M mixed securities shelf - TheFly
- 6 weeks ago - Evolus Registration statement: Registration filing - Filings
- 6 weeks ago - Evolus management to meet virtually with BTIG - TheFly
- 6 weeks ago - Evolus Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts